CCR7 介导的模拟树突状细胞疫苗归巢至淋巴结用于头颈部鳞状细胞癌治疗
CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy.
免疫疗法已被公认为头颈部鳞状细胞癌(HNSCC)最有前景的治疗策略之一。
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy.
免疫疗法已被公认为头颈部鳞状细胞癌(HNSCC)最有前景的治疗策略之一。
Applications of mRNA Delivery in Cancer Immunotherapy.
癌症治疗不断进步,免疫治疗作为一种标准模式日益突出,已显著改善多种恶性肿瘤的治疗。
Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive
PEX mRNA特征可能可用作nivolumab的伴随诊断。抗NKG2A抗体(即monalizumab)与nivolumab的联合可能作为基于RT-qPCR的PEX mRNAs治疗前检测所预测的非存活者的一种治疗选择。
Review of biomarkers for response to immunotherapy in HNSCC microenvironment.
头颈部鳞状细胞癌是全球最常见的癌症类型之一。
Potassium channels mediate the inhibitory effect of exosomes on anti-tumor immunity in head and neck cancer.
头颈部鳞状细胞癌(HNSCC)是侵袭性癌症,对免疫治疗的反应率相对较低。
MEMBER ACCOUNT
登录成功会直接打开下一页。